Remon J - Search Results

1

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.

Remon J, Planchard D. Remon J, et al. Future Oncol. 2015 Nov;11(22):3069-81. doi: 10.2217/fon.15.250. Epub 2015 Oct 9. Future Oncol. 2015. PMID: 26450446 Review.

2

Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.

Reguart N, Remon J. Reguart N, et al. Among authors: remon j. Future Oncol. 2015;11(8):1245-57. doi: 10.2217/fon.15.15. Epub 2015 Jan 28. Future Oncol. 2015. PMID: 25629371 Review.

3

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.

Remon J, Gazzah A, Besse B, Soria JC. Remon J, et al. J Thorac Oncol. 2015 Aug;10(8):e72-3. doi: 10.1097/JTO.0000000000000561. J Thorac Oncol. 2015. PMID: 26200282 Free article. No abstract available.

4

Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?

Remon J, Gorham J, Besse B, Sculier JP. Remon J, et al. Eur Respir J. 2015 Dec;46(6):1548-50. doi: 10.1183/13993003.01482-2015. Eur Respir J. 2015. PMID: 26621882 Free article. No abstract available.

5

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.

Remon J, Chaput N, Planchard D. Remon J, et al. Curr Opin Oncol. 2016 Mar;28(2):122-9. doi: 10.1097/CCO.0000000000000263. Curr Opin Oncol. 2016. PMID: 26756384 Review.

6

The 5000% case: a glimpse into the financial issue of lung cancer treatment.

Remon J, Bonastre J, Besse B. Remon J, et al. Eur Respir J. 2016 May;47(5):1331-3. doi: 10.1183/13993003.00548-2016. Eur Respir J. 2016. PMID: 27132267 Free article. No abstract available.

7

Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.

Facchinetti F, Caramella C, Auger N, Planchard D, Adam J, Lacroix L, Remon J, Massard C, Soria JC, Friboulet L, Besse B. Facchinetti F, et al. Among authors: remon j. Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000520. Tumori. 2016. PMID: 27197808

8

Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.

Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B. Remon J, et al. Lung Cancer. 2016 Jul;97:99-104. doi: 10.1016/j.lungcan.2016.04.024. Epub 2016 May 3. Lung Cancer. 2016. PMID: 27237035

9

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.

Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L. Facchinetti F, et al. Among authors: remon j. Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11. Clin Cancer Res. 2016. PMID: 27401242 Clinical Trial.

10

Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options.

Remon J, Besse B. Remon J, et al. ESMO Open. 2016 Aug 1;1(4):e000081. doi: 10.1136/esmoopen-2016-000081. eCollection 2016. ESMO Open. 2016. PMID: 27843631 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

651 results

Search Page

Filters